Conexiant’s news site is now MDSpire News. Learn more
Advertisement
GLP-1 RAs Associated With Small ION Risk Increase
In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.
Initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was linked to a higher adjusted 18-month risk of ischemic optic neuropathy (ION) compared to sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in a large observational analysis of commercially insured US adults with type 2 diabetes. The absolute difference in risk was approximately 3 to 4 cases per 10,000 patients.
Background
The association between GLP-1 RAs and ischemic optic neuropathy is due to the increasing use of these medications in managing type 2 diabetes. This study adds to the evidence regarding the safety profile of GLP-1 RAs, particularly concerning ocular health.
Data Highlights
Medication
ION Risk per 10,000
GLP-1 RA
9
SGLT2 Inhibitor
6
DPP-4 Inhibitor
4
Key Findings
GLP-1 RA initiators had an adjusted cumulative risk of ION of approximately 9 cases per 10,000.
The risk for SGLT2 inhibitor initiators was about 6 cases per 10,000, resulting in a difference of 3 cases per 10,000.
Among DPP-4 inhibitor initiators, the risk was approximately 4 cases per 10,000, leading to a difference of about 4 cases per 10,000 compared to GLP-1 RAs.
85% of ION events in GLP-1 RA initiators occurred in patients older than 50 years.
Numerically larger risk differences were observed among patients with preexisting ocular conditions.
Specific outcome definitions reduced the adjusted risk differences, indicating potential residual confounding.
Clinical Implications
Healthcare providers should be aware of the potential increased risk of ischemic optic neuropathy associated with GLP-1 RA initiation.
Conclusion
This study highlights a potential association between GLP-1 RAs and an increased risk of ischemic optic neuropathy, necessitating further research to clarify these findings and their clinical significance.
Preoperative use was associated with fewer revisions and no increase in short-term complications among patients with obesity, although benefits appeared concentrated in select subgroups.
From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.
Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer, and mortality across three large cohorts.
